Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
Scott Dreyer, the Executive Vice President and Chief Commercial Officer at Collegium Pharmaceutical , Inc. (NASDAQ:COLL), recently sold 15,387 shares of the company’s common stock. The transaction, which took place on March 6, 2025, was executed at a weighted average price of $30.004 per share, totaling approximately $461,671.
This sale was carried out under a pre-established Rule 10b5-1 trading plan that Dreyer adopted on August 28, 2024. Following this transaction, Dreyer now holds 126,676 shares of Collegium Pharmaceutical directly. While this insider transaction draws attention, InvestingPro data reveals that management has been actively buying back shares, and analysts have recently revised earnings estimates upward. For comprehensive insider trading analysis and 8 additional ProTips, explore the detailed Pro Research Report available on InvestingPro.
In other recent news, Collegium Pharmaceuticals reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $1.75 compared to the forecast of $1.66. The company also exceeded revenue projections, posting $181.9 million against the anticipated $179.48 million. Collegium Pharmaceuticals demonstrated robust performance in Q4 2024, with net product revenues reaching a record $181.9 million, marking a 22% year-over-year increase. The company’s annual revenue for 2024 was $631.4 million, an 11% rise from the previous year, driven by strong demand for its ADHD medication, Jornay, and its pain management products, BELBUCA and Xtampza ER. Adjusted EBITDA for 2024 was $401.2 million, a 9% increase from the previous year. For 2025, Collegium projects net product revenue between $735 million and $750 million, with adjusted EBITDA expected to grow by over 10%, reaching between $435 million and $450 million. The company plans to expand its sales force and invest in digital marketing to drive further growth, particularly for its ADHD and pain management portfolios.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.